Health Care · Surgical & Medical Instruments & Apparatus

PRCT PROCEPT BioRobotics Corp SEC Filings & Insider Trading Activity 2026

company
CIK 158897873 filings
Russell 2000

PRCT at a glance

PROCEPT BioRobotics Corp (PRCT, SEC CIK 1588978) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), PROCEPT BioRobotics Corp (PRCT) reported revenue of $308.1 million (up 37.2% from FY2024) and a net loss of $95.6 million. Diluted EPS was -$1.72.
  • As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding PROCEPT BioRobotics Corp (PRCT) shares worth $399.1 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Sharma Pooja on November 6, 2026 of 4,710 shares at $19.71 per share.
  • In the last 90 days, PRCT insiders reported 0 open-market purchases ($0) and 4 open-market sales ($115K) on Form 4, a net sale of $115K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$308.1M
+37.2% vs prior year
Insiders · 90 days
0 buys · 4 sells
Net −$115K
13F holders
25 funds
$399.1M · −4 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Develops and sells AquaBeam and HYDROS robotic systems for minimally invasive urologic surgery focused on benign prostatic hyperplasia (BPH) treatment
  • New emphasis on prostate cancer treatment with ongoing clinical trials including the pivotal WATER IV PCa randomized FDA-approved IDE study
  • Strategic shift toward global expansion and increased efforts in private payor coverage and direct-to-patient marketing beyond urologists
  • Install base growth to 912 robotic systems globally as of Dec 31, 2025, up from prior years, with revenue rising to $308.1 million in 2025
  • Notable investment in AI and machine learning to improve treatment planning and product scalability for future innovation

Risk Factors

  • FDA regulatory risk: ongoing need to comply with FDA requirements for marketing approval and labeling limitations affecting product acceptance
  • Macroeconomic exposure: sales dependent on U.S. hospital and surgeon adoption, limited international presence, market growth constrained by reimbursement variability
  • Supply chain risk: reliance on third-party distributors and suppliers for timely product components and distribution in targeted markets
  • Market disruption threat: competition from established surgical alternatives and emerging robotic or medical technologies impacting surgeon and hospital adoption
  • Financial risk: $52M term loan with restrictive covenants and $286.5M cash on hand with $641.6M accumulated deficit, risking liquidity if covenants breached or capital markets tighten

Management Discussion & Analysis

  • Revenue $308.1M, up 37% YoY from $224.5M; system sales up $15.8M (18%), hand-piece sales up $60.0M (49%)
  • Gross margin 64% vs 61% YoY, cost of sales up 28% to $111.8M driven by higher volume and warranty costs
  • Best segment: hand-pieces with $181.4M revenue, worst: systems at $106.1M; service revenue $20.5M up 61%
  • Operating expenses up 28% to $300.1M; R&D $71.3M (+14%), SG&A $228.8M (+33%) due to sales/marketing expansion
  • Net loss $95.6M vs $91.4M; operating loss $103.9M vs $96.6M; interest expense down 14% to $3.6M; net interest/income up 24% to $12.1M
  • Cash $286.5M, loan outstanding $52.0M; net cash used in operating activities $49.0M; financing inflow $11.2M from stock and ESPP
  • Management expects continued revenue growth from expanding robotic install base and system utilization, investing in R&D and sales infrastructure
  • Risks: reimbursement coverage, cost management, regulatory approval, market competition, and funding needs remain key uncertainties

AI summary of the PRCT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to previously disclosed risk factors during nine months ended September 30, 2026
  • Healthcare industry risks remain relevant to business, financial condition, and operating results
  • Unknown or currently immaterial risks could materially adversely affect results
  • Historical financial performance may not reliably indicate future results

Management Discussion & Analysis

  • Quarterly revenue $98.3M, up 18% YoY from $83.3M
  • Gross margin 66% vs 65% YoY, including $3.2M tariff refunds
  • Best line handpieces and consumables $60.8M, up from $49.7M; weakest systems $29.2M vs $28.1M
  • Operating cash flow $(66.4)M for nine months vs $(38.7)M; investing outflow $6.5M
  • Cash $218.4M; management expects funding through at least the next twelve months, with higher sales, marketing and R&D spending ahead

AI summary of the PRCT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces PROCEPT BioRobotics’ financial results for the quarter ended September 30, 2026
  • Full quarterly results available in Exhibit 99.1, including operating performance and financial metrics

Item EX-99.1: Item EX-99.1

  • Q3 revenue $98.3M, up 18%, led by U.S. consumables up 21% and international revenue up 32%
  • U.S. procedures 13,400, up 22%, with 62 HYDROS systems delivered and 106% handpieces per procedure
Filed Oct 2, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board expanded from 9 to 10 directors, adding governance capacity and an independent voice
  • Dr. Michael Mack appointed Class II director, serving through the 2029 annual meeting
Filed Sep 24, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • CIBC term-loan maturity extended 12 months, from October 1, 2027 to October 1, 2028
  • Added financing runway reduces near-term refinancing pressure

AI summaries of PRCT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for PRCT

Don't miss the next PRCT filing

  • Alerts as it files. A push when PRCT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut PRCT, by share count.
  • Ask anything. An AI agent that reads every PRCT filing and answers with sources.

PRCT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Sharma PoojaSellNov 6, 2026$19.71
Mack MichaelAOct 2, 2026-
Mack MichaelAOct 2, 2026-
Nouri AlalehSellSep 9, 2026$20.95
Waters KevinSellSep 9, 2026$20.95
Templin Barry LSellSep 9, 2026$20.95
Waters KevinAAug 13, 2026-
Nouri AlalehAAug 13, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$224.5M$308.1M
Gross Profit-$137.1M$196.2M
Operating Income--$96.6M-$103.9M
Net Income--$91.4M-$95.6M
Gross Margin-61.1%63.7%
Op. Margin--43.0%-33.7%
Net Margin--40.7%-31.0%
Balance Sheet
Total Assets$404.7M$534.0M$508.1M
Equity$280.8M$402.2M$365.9M
ROE--22.7%-26.1%
Per Share
EPS-$-1.75$-1.72
Cash Flow
Operating CF--$99.2M-$49.0M
CapEx-$4.4M$9.4M

Source: XBRL data in PROCEPT BioRobotics Corp (PRCT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate PRCT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
PRCT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202625$399.1M
Q2 202629$432.6M
Q1 202627$456.5M
Q4 202525$649.6M
Q3 202526$872.4M
Q2 202528$1.44B
Q1 202527$1.22B
Q4 202423$1.55B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 210 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

PRCT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 6, 2026--
8-KNov 4, 2026Analysis-
10-QNov 4, 2026Analysis
4Oct 5, 2026--
8-KOct 2, 2026Analysis-
8-KSep 24, 2026Analysis-
4Sep 10, 2026--
4Sep 10, 2026--
4Sep 10, 2026--
4Aug 14, 2026--
4Aug 14, 2026--
4Aug 14, 2026--
4Aug 14, 2026--
4Aug 10, 2026--
10-QAug 5, 2026Analysis
8-KAug 4, 2026Analysis-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
8-KJun 10, 2026Analysis
4Jun 10, 2026-
4Jun 10, 2026-

Related Health Care companies

All Health Care →

PRCT SEC filings: frequently asked questions

Are PRCT insiders buying or selling?

In the last 90 days, PROCEPT BioRobotics Corp (PRCT) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $114,707 by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold PRCT stock?

As of September 30, 2026, the largest PROCEPT BioRobotics Corp (PRCT) holders among the 13F filers tracked by SignalX were BlackRock ($88.3 million), Vanguard Portfolio Management LLC ($44.9 million), Vanguard Capital Management LLC ($44.0 million), JPMorgan Chase & Co ($34.8 million), State Street Corp ($30.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was PRCT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), PROCEPT BioRobotics Corp (PRCT) reported revenue of $308.1 million (up 37.2% from FY2024) and a net loss of $95.6 million. Diluted EPS was -$1.72. The figures come from the XBRL data in the 10-K.

What are the main risks in PRCT's latest 10-K?

In the 10-K filed February 26, 2026, PROCEPT BioRobotics Corp (PRCT) flagged: FDA regulatory risk: ongoing need to comply with FDA requirements for marketing approval and labeling limitations affecting product acceptance. Macroeconomic exposure: sales dependent on U.S. hospital and surgeon adoption, limited international presence, market growth constrained by reimbursement variability. (AI summary of the Risk Factors section.)

What did PRCT report in its latest 8-K?

PROCEPT BioRobotics Corp (PRCT) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces PROCEPT BioRobotics’ financial results for the quarter ended September 30, 2026.

What are the latest PRCT SEC filings?

PROCEPT BioRobotics Corp (PRCT) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 6, 2026.

What is PRCT's SEC CIK number?

PROCEPT BioRobotics Corp (PRCT)'s SEC Central Index Key (CIK) is 1588978. EDGAR lists every PRCT filing under that number.

Ask anything about PRCT

The research agent reads PRCT's filings, financials, insider trades and 13F holders, then answers with sources.